RT Journal Article
SR Electronic
T1 Multi-omics characterization of type 2 diabetes associated genetic variation
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.07.15.24310282
DO 10.1101/2024.07.15.24310282
A1 Mandla, Ravi
A1 Lorenz, Kim
A1 Yin, Xianyong
A1 Bocher, Ozvan
A1 Huerta-Chagoya, Alicia
A1 Arruda, Ana Luiza
A1 Piron, Anthony
A1 Horn, Susanne
A1 Suzuki, Ken
A1 Hatzikotoulas, Konstantinos
A1 Southam, Lorraine
A1 Taylor, Henry
A1 Yang, Kaiyuan
A1 Hrovatin, Karin
A1 Tong, Yue
A1 Lytrivi, Maria
A1 Rayner, Nigel W.
A1 Meigs, James B.
A1 McCarthy, Mark I.
A1 Mahajan, Anubha
A1 Udler, Miriam S.
A1 Spracklen, Cassandra N.
A1 Boehnke, Michael
A1 Vujkovic, Marijana
A1 Rotter, Jerome I.
A1 Eizirik, Decio L.
A1 Cnop, Miriam
A1 Lickert, Heiko
A1 Morris, Andrew P.
A1 Zeggini, Eleftheria
A1 Voight, Benjamin F.
A1 Mercader, Josep M.
YR 2024
UL http://medrxiv.org/content/early/2024/07/15/2024.07.15.24310282.abstract
AB Discerning the mechanisms driving type 2 diabetes (T2D) pathophysiology from genome-wide association studies (GWAS) remains a challenge. To this end, we integrated omics information from 16 multi-tissue and multi-ancestry expression, protein, and metabolite quantitative trait loci (QTL) studies and 46 multi-ancestry GWAS for T2D-related traits with the largest, most ancestrally diverse T2D GWAS to date.Of the 1,289 T2D GWAS index variants, 716 (56%) demonstrated strong evidence of colocalization with a molecular or T2D-related trait, implicating 657 cis-effector genes, 1,691 distal-effector genes, 731 metabolites, and 43 T2D-related traits. We identified 773 of these cis- and distal-effector genes using either expression QTL data from understudied ancestry groups or inclusion of T2D index variants enriched in underrepresented populations, emphasizing the value of increasing population diversity in functional mapping. Linking these variants, genes, metabolites, and traits into a network, we elucidated mechanisms through which T2D-associated variation may impact disease risk. Finally, we showed that drugs targeting effector proteins were enriched in those approved to treat T2D, highlighting the potential of these results to prioritize drug targets for T2D.These results represent a leap in the molecular characterization of T2D-associated genetic variation and will aid in translating genetic findings into novel therapeutic strategies.Competing Interest StatementJ.B.M is an academic associate for Quest Diagnostics Inc. Endocrine R&D. MIMcC is now an employee of Genentech and a holder of Roche stock.Funding StatementA.H. is supported by the American Diabetes Association grant #11-23-PDF-35. O.B. has received funding from the European Unions Horizon 2020 research and innovation programme under Grant Agreement No 101017802 (OPTOMICS). A.P. is supported by the Wiener-Anspach Foundation, and the Fonds National de la Recherche Scientifique (FNRS). J.B.M is supported by NIDDK (U01DK078616 and R01DK078616). J.M.M. is supported by American Diabetes Association Innovative and Clinical Translational Award 1-19-ICTS-068, American Diabetes Association grant #11-22-ICTSPM-16, by NHGRI (U01HG011723), NIDDK (UM1-DK078616) and Medical University of Bialystok (MUB) grant from the Ministry of Science and Higher Education (Poland). This study also supported in part by the National Center for Advancing Translational Sciences, CTSI grant UL1TR001881, and the National Institute of Diabetes and Digestive and Kidney Disease Diabetes Research Center (DRC) grant DK063491 to the Southern California Diabetes Endocrinology Research Center. Infrastructure for the CHARGE Consortium is supported in part by the National Heart, Lung, and Blood Institute (NHLBI) grant R01HL105756. This research was conducted in part using data and resources from the Framingham Heart Study of the National Heart Lung and Blood Institute of the National Institutes of Health and Boston University School of Medicine. The Framingham Heart Study (FHS) acknowledges the support of contracts NO1-HC-25195, HHSN268201500001I and 75N92019D00031 from the National Heart, Lung and Blood Institute and grant supplement R01 HL092577-06S1 for this research.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study used ONLY openly available human summary statistics data described in Supplementary Table 1 and human gene expression data downloaded from GEO accession number GSE159984 and the Islet Expression HPAP project.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript